Taylor and Francis Group, OncoImmunology, 12(4), p. e1053684
DOI: 10.1080/2162402x.2015.1053684
Full text: Download
Chimeric Antigen Receptor (CAR) T cells have enjoyed unprecedented clinical success for haematological malignancies in recent years. However several aspects of CAR T cell biology remain unknown. We compared CAR and TCR killing in the same effector cell and showed that CAR T cells can not only efficiently kill single tumor targets, they can also kill multiple tumor targets in a sequential manner. Single and serial killing events were not sustained over the long term due to CAR down-regulation after 20 hours.